FermorFermorSearch 14,000+ schemesSign up free
Fermor/Mutual Funds/Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth
AB

Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth

Equity Scheme - Sectoral/ ThematicDirect Plan, Growth optionVery High Risk
39.49NAV as of 17 Jul 2026Data refreshed 8 hours ago
+16.39%over 1Y

Plotted from the real NAV points Fermor has on record for this scheme, not an interpolated daily series.

NAV date
17 Jul 2026
Fund size (AUM)
₹180.76 Cr
Plan / option
Direct Plan, Growth option
Risk (category)
Very High

Investment growth calculator

See what a monthly SIP could grow to using this fund's own trailing returns, or check what a real historical lumpsum investment would be worth today.

Monthly investment
₹5,000
Total invested₹6,00,000
Would grow to₹12,83,046
Est. gains₹6,83,046 (113.8%)

Projected using Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth's own trailing 5 years annualised return (+14.54%). Actual future returns will vary.

Want a fuller projection with your own assumptions? Use the SIP Calculator or Lumpsum Calculator.

Are you a CA or financial advisor?

Generate branded Tax Optimization Reports for your clients.

Get started free

Returns and Rankings

Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth has returned +15.4% over the 1 year to 17 Jul 2026, based on AMFI's historical NAV data.

Returns and Rankings
Fund returns versus category average and rank
Name1Y3Y5Y
Fund returns+15.40%+23.85%+14.54%
Category average (Equity Scheme - Sectoral/ Thematic)+6.29%+17.92%+14.36%
Rank (Equity Scheme - Sectoral/ Thematic)24 of 21414 of 12344 of 96

Rank and category average are computed live from every AMFI-registered Direct Plan, Growth option scheme sharing this fund's category, not sourced from a third party.

Category Position: Where This Fund Sits Among Its Peers
1 yearRank 24 of 214 · top 12%
Best in categoryLowest
3 yearsRank 14 of 123 · top 12%
Best in categoryLowest
5 yearsRank 44 of 96 · top 46%
Best in categoryLowest

Advanced Ratios

Computed over the last 12 months (368 days, 247 aligned NAV points) of this fund's own real daily NAV against the Nifty 50, using India's 10-year G-Sec yield (6.8%) as the risk-free rate. This is a shorter window than most competitor sites use (typically 3-5 years), so Sharpe and Sortino can look quite different when recent returns have been weak: we'd rather show the window than hide it.

Advanced Ratios (1Y)
Alpha
15.11
Beta
0.56
Sharpe
0.77
Sortino
0.76

1-year window · vs Nifty 50 · risk-free rate 6.8% (10Y G-Sec).

Exit Load, Stamp Duty and Tax

Every purchase carries a flat 0.005% stamp duty. Exit load, charged only within a certain holding period, is set by the AMC per scheme and disclosed in its SID: check there before redeeming if timing matters.

This is an equity-oriented scheme for tax purposes. Gains on units held for more than 12 months are long-term capital gains (LTCG), exempt up to Rs 1.25 lakh in aggregate per financial year across all equity shares and equity mutual funds, and taxed at 12.5% on the excess.

Compare Similar Funds

Select up to three peers from the same category to compare side by side with this fund.

Similar funds in the same category
SelectNameNAV1Y Return
360 ONE QUANT FUND DIRECT GROWTH
360 ONE Mutual Fund
19.55-4.26%
Axis Business Cycles Fund - Direct Plan - Growth
Axis Mutual Fund
17.65+3.52%
Axis Consumption Fund Direct Plan - Growth
Axis Mutual Fund
9.40-1.36%
Axis ESG Integration Strategy Fund - Direct Plan - Growth Option
Axis Mutual Fund
22.79-0.44%
Axis India Manufacturing Fund - Direct Plan - Growth
Axis Mutual Fund
15.86+12.16%
Axis Innovation Fund - Direct Plan - Growth Option
Axis Mutual Fund
21.71+9.98%

Peers are AMFI-registered schemes in the same category from different AMCs; NAV and 1-year return are computed from the same daily AMFI feed as this page. Risk shown for peers reflects the shared category, not an individually disclosed riskometer reading. AAUM is only sourced for this page's own scheme today.

What Is NAV?

NAV is the per-unit price of Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth, published daily under SEBI and AMFI rules. See how mutual fund NAV is calculated for the full mechanics.

This is an equity scheme, investing predominantly in listed stocks, with returns tied to broader equity market performance.

How to Invest in Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth

Investing follows the same five-step process for any AMFI-registered scheme: complete KYC once, choose Direct or Regular, decide lumpsum or SIP using the calculator above, choose Growth or IDCW, then submit through the AMC, a registered platform, or an RTA. See the full step-by-step guide to investing in mutual funds for detail on each step, including the Direct vs Regular and Growth vs IDCW tradeoffs.

Minimum investment amounts (commonly Rs 100-500 for SIPs and Rs 1,000-5,000 for a lumpsum) are set by each AMC and disclosed in the SID; confirm the exact figure for this scheme before investing.

More Funds From Aditya Birla Sun Life Mutual Fund

Use the SIP Calculator to project returns from a monthly investment in this category, the Lumpsum Calculator for a one-time investment, the CAGR Calculator to work out the annualised return you have actually earned, and the XIRR Calculator for a series of SIP instalments made on different dates.

Are you a CA or financial advisor?

Generate branded Tax Optimization Reports for your clients.

Get started free

Frequently Asked Questions

What is the NAV of Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth?

The NAV of Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth is Rs 39.4900 per unit as of 17 Jul 2026, per AMFI's daily NAV data.

What has been the return of Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth?

Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth returned +15.4% over the 1 year to 17 Jul 2026. Periods of 1 year or longer are annualised; shorter periods are point-to-point.

How does Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth rank against similar funds?

Over 3 years, Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth ranks 14 of 123 Direct Plan, Growth option schemes in the "Equity Scheme - Sectoral/ Thematic" category, computed live from real AMFI NAV data across every fund in the category.

What does the category "Equity Scheme - Sectoral/ Thematic" mean?

This is an equity scheme, investing predominantly in listed stocks, with returns tied to broader equity market performance.

How risky is Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth?

Funds in the "Equity Scheme - Sectoral/ Thematic" category are typically placed at Very High risk on SEBI's mandatory product riskometer. SEBI's product riskometer methodology weighs equity allocation and volatility heavily, so pure equity categories including this one are almost universally placed Very High, regardless of market-cap focus.

How are gains from Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth taxed?

This is an equity-oriented scheme for tax purposes. Gains on units held for more than 12 months are long-term capital gains (LTCG), exempt up to Rs 1.25 lakh in aggregate per financial year across all equity shares and equity mutual funds, and taxed at 12.5% on the excess.

What are similar funds to Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth?

Other AMCs run schemes in the same "Equity Scheme - Sectoral/ Thematic" category, including 360 ONE QUANT FUND DIRECT GROWTH, Axis Business Cycles Fund - Direct Plan - Growth, Axis Consumption Fund Direct Plan - Growth. Compare their NAV and 1-year returns in the "Compare Similar Funds" section on this page.

Disclaimer: NAV and historical return data is sourced from AMFI and refreshed daily. Risk profile and tax treatment described on this page are general, category-level information, not this specific scheme's officially disclosed riskometer level or individualised tax advice. Category average and rank are computed live from real AMFI NAV data across the category and may include or exclude schemes depending on what history Fermor has recorded for each one. Mutual fund investments are subject to market risk. Past performance does not indicate future returns. This page is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered investment adviser or a chartered accountant before making investment or tax decisions.

Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth
39.4900 NAV
Save this fund